BAC
Bank of America Corporation
BAC has the edge over MRBK overall, supported by stronger valuation and stronger modeled upside.
MRBK
Meridian Corporation
MRBK trails on the overall score without a compensating advantage in the available component scores.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MRBK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
MRBK's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MRBK.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over MRBK in the historical PE scenario, which offers more potential upside but is not a forecast.
MRBK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $10.15 | -39% |
| Fair | 8.2x | $13.80 | -16% |
| Current | 9.8x | $16.51 | — |
| Forward | 9.8x | $16.51 | — |
| Expensive | 10x | $17.49 | +5.9% |
Historical ranges are pointers, not guarantees.
MRBK's PE is in its expensive range at 9.8x. On analysts' estimates for next year's earnings, today's price would be 9.8x.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over MRBK on the outlook, with more favorable valuation and earnings expectations.
MRBK Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect MRBK's earnings and profitability to decline, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
MRBK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.69 | 0% |
| Q3 2026 | $1.69 | -4.5% |
| Q2 2026 | $1.84 | +14% |
| Q1 2026 | $1.85 | +30% |
| Q4 2025 | $1.89 | +30% |
| Q3 2025 | $1.77 | +74% |
| Q2 2025 | $1.61 | +69% |
| Q1 2025 | $1.42 | +34% |
| Q4 2024 | $1.45 | +25% |
MRBK's earnings per share have fallen from their peak: $1.69 over the past year, against $2.96 in mid-2021.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over MRBK on profitability, with a higher operating margin.
MRBK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.1M | -8.9% |
| Q2 2026 | $32.7M | +0.7% |
| Q1 2026 | $30.2M | +12% |
| Q4 2025 | $34.2M | +5.1% |
| Q3 2025 | $33.1M | +14% |
| Q2 2025 | $32.4M | +24% |
| Q1 2025 | $27.1M | +10% |
| Q4 2024 | $32.6M | +30% |
MRBK's revenue fell from its 2020 peak and has held roughly level since: $30M last quarter, down 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -6.4 points |
| Q2 2026 | 23% | +0.4 points |
| Q1 2026 | 8.6% | -3 points |
| Q4 2025 | 27% | +3.8 points |
| Q3 2025 | 26% | +4.8 points |
| Q2 2025 | 22% | +5.6 points |
| Q1 2025 | 12% | -2.8 points |
| Q4 2024 | 23% | +20 points |
MRBK's operating margin was 20% last quarter, down 6.4 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over MRBK on cash flow, with more consistent year-over-year improvement.
MRBK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.4M | -48% |
| Q2 2026 | -$1.4M | +$11.3M |
| Q1 2026 | $2.6M | -85% |
| Q4 2025 | -$6.6M | -$5.5M |
| Q3 2025 | $24M | -27% |
| Q2 2025 | -$12.7M | +$6.6M |
| Q1 2025 | $17.9M | +$21.5M |
| Q4 2024 | -$1.1M | -115% |
MRBK's free cash flow was $7M over the past year, down 75% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MRBK.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MRBK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MRBK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +48K shares |
| 1 year | +5.9% | +682K shares |
| 3 years | +7.6% | +859K shares |
| 5 years | -1.9% | -240K shares |
MRBK has 12M diluted shares, up 5.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $1,000 |
| Q2 2023 | $1.6M |
| Q1 2023 | $2.7M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MRBK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | 10.1x | High |
| Q4 2019 | 9.6x | High |
MRBK's net debt is about 10 years of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like MRBK.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MRBK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 15.5 | Oversold |
MRBK's weekly RSI is 32 (neutral) and its Stochastic is 16 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
MRBK PE vs Financial Services Sector
| Metric | MRBK | Sector median | Relative |
|---|---|---|---|
| PE | 9.8x | 13x | 25% below |
| PE % | 71 | 63 | 8 pts above |
MRBK has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
MRBK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.2 | 9.4% below |
| 20 week MA | $19.1 | 14% below |
| 50 week MA | $18.9 | 13% below |
| 100 week MA | $16.7 | 1% below |
| 200 week MA | $14.2 | 16% above |
MRBK has fallen below most of its moving averages, though it's still 16% above its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
MRBK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.88 | $10.4 | +5.1% |
| 2021 | $10.4 | $17.7 | +70% |
| 2022 | $17.7 | $15.0 | -15% |
| 2023 | $15.0 | $13.9 | -7.5% |
| 2024 | $13.9 | $13.4 | -3.6% |
| 2025 | $13.4 | $17.6 | +31% |
| 2026 YTD | $17.6 | $16.5 | -6.3% |
MRBK has the edge over BAC on returns for 2026, with the stronger performance.